Structural Speciation of Ti(IV)-(α-Hydroxycarboxylic Acid) Complexes in Metabolism-Related (Patho)Physiology—In Vitro Approaches to (Pre)Adipocyte Differentiation and Mineralization

The prospect of developing soluble and bioavailable Ti(IV) complex forms with physiological substrates, capable of influencing (patho)physiological aberrations, emerges as a challenge in the case of metabolism-related pathologies (e.g., diabetes mellitus 1 and 2). To that end, pH-specific synthetic efforts on binary Ti(IV)-(α-hydroxycarboxylic acid) systems, involving natural physiological chelator ligands (α-hydroxy isobutyric acid, D-quinic acid, 2-ethyl-2-hydroxybutyric acid) in aqueous media, led to the successful isolation of binary crystalline Ti(IV)-containing products. The new materials were physicochemically characterized by elemental analysis, FT-IR, TGA, and X-ray crystallography, revealing in all cases the presence of mononuclear Ti(IV) complexes bearing a TiO6 core, with three bound ligands of variable deprotonation state. Solution studies through electrospray ionization mass spectrometry (ESI-MS) revealed the nature of species arising upon dissolution of the title compounds in water, thereby formulating a solid-state–solution correlation profile necessary for further employment in biological experiments. The ensuing cytotoxicity profile (pre-adipocytes and osteoblasts) of the new materials supported their use in cell differentiation experiments, thereby unraveling their structure-specific favorable effect toward adipogenesis and mineralization through an arsenal of in vitro biological assays. Collectively, well-defined atoxic binary Ti(IV)-hydroxycaboxylato complexes, bearing bound physiological substrates, emerge as competent inducers of cell differentiation, intimately associated with cell maturation, thereby (a) associating the adipogenic (insulin mimetic properties) and osteogenic potential (mineralization) of titanium and (b) justifying further investigation into the development of a new class of multipotent titanodrugs.

[1]  O. Tsave,et al.  Biomimetic activity of soluble, well-defined, aqueous Ti(IV)-citrate species toward adipogenesis. An in vitro study. , 2020, Journal of inorganic biochemistry.

[2]  Justin J. Wilson,et al.  Metal complexes as a promising source for new antibiotics , 2019, Chemical science.

[3]  Yujie Sun,et al.  Dual-Functional Implants with Antibacterial and Osteointegration-Promoting Performances. , 2019, ACS applied materials & interfaces.

[4]  T. Kiss,et al.  Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties. , 2019, Current medicinal chemistry.

[5]  O. Tsave,et al.  Synthetic exploration of the binary cadmium-quinic acid system linked to in vitro cytotoxicity and chelation cytoprotection investigation , 2018, Inorganica Chimica Acta.

[6]  O. Tsave,et al.  Comparative assessment of metal-specific adipogenic activity in zinc and vanadium-citrates through associated gene expression. , 2018, Journal of inorganic biochemistry.

[7]  O. Tsave,et al.  Synthetic endeavors on cadmium species bearing glycolate and aromatic chelators with structure-specific biotoxic correlations in vitro. , 2017, Journal of inorganic biochemistry.

[8]  Y. Miao,et al.  Review: recent advances and future development of metal complexes as anticancer agents , 2017 .

[9]  V. Gandin,et al.  Anticancer activity of a series of copper(II) complexes with tripodal ligands. , 2017, European journal of medicinal chemistry.

[10]  O. Tsave,et al.  The adipogenic potential of Cr(III). A molecular approach exemplifying metal-induced enhancement of insulin mimesis in diabetes mellitus II. , 2016, Journal of inorganic biochemistry.

[11]  J. Domingo,et al.  Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  M. Hanif,et al.  Development of anticancer agents: wizardry with osmium. , 2014, Drug discovery today.

[13]  A. Salifoglou,et al.  Structure Lattice-Dimensionality and Spectroscopic Property Correlations in Novel Binary and Ternary Materials of Group 13 Elements with α-Hydroxycarboxylic Benzilic Acid and Phenanthroline , 2014 .

[14]  Zijian Guo,et al.  Metal-based anticancer chemotherapeutic agents. , 2014, Current opinion in chemical biology.

[15]  Juliana Ribeiro Pala Jorge,et al.  Titanium in Dentistry: Historical Development, State of the Art and Future Perspectives , 2013, Journal of Indian Prosthodontic Society.

[16]  Roy Taylor.  Insulin Resistance and Type 2 Diabetes , 2012, Diabetes.

[17]  A. Saghatelian,et al.  Cytotoxicity of a Ti(IV) compound is independent of serum proteins , 2012, Proceedings of the National Academy of Sciences.

[18]  C. Su,et al.  The balance between adipogenesis and osteogenesis in bone regeneration by platelet-rich plasma for age-related osteoporosis. , 2011, Biomaterials.

[19]  T. Huhn,et al.  Titanium Salan Complexes Displays Strong Antitumor Properties In Vitro and In Vivo in Mice , 2011, PloS one.

[20]  E. Hey‐Hawkins,et al.  Titanium(IV) carboxylate complexes: Synthesis, structural characterization and cytotoxic activity , 2010 .

[21]  I. Fichtner,et al.  Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice , 2008 .

[22]  A. Salifoglou,et al.  Synthetic, structural, spectroscopic and solution speciation studies of the binary Al(III)–quinic acid system. Relevance of soluble Al(III)–hydroxycarboxylate species to molecular toxicity , 2008 .

[23]  G. Duque.  Bone and fat connection in aging bone , 2008, Current opinion in rheumatology.

[24]  A. Salifoglou,et al.  Delving into the complex picture of Ti(IV)–citrate speciation in aqueous media: Synthetic, structural, and electrochemical considerations in mononuclear Ti(IV) complexes containing variably deprotonated citrate ligands , 2008 .

[25]  H. Müller‐Bunz,et al.  Oxali‐Titanocene Y: A Potent Anticancer Drug , 2008, ChemMedChem.

[26]  M. Shavit,et al.  Preparation and X‐ray Structures of TiIV Complexes of Bis(carboxylato) Ligands – Formation of Mono‐, Di‐, Tetra‐, and Hexanuclear Complexes with or without OR and μ‐O Ligands , 2008 .

[27]  Gervais Chapuis,et al.  SUPERFLIP– a computer program for the solution of crystal structures by charge flipping in arbitrary dimensions , 2007 .

[28]  Yuan Deng,et al.  Speciation of water-soluble titanium citrate: Synthesis, structural, spectroscopic properties and biological relevance , 2007 .

[29]  A. Salifoglou,et al.  Mononuclear titanium(IV)-citrate complexes from aqueous solutions: pH-specific synthesis and structural and spectroscopic studies in relevance to aqueous titanium(IV)-citrate speciation. , 2005, Inorganic chemistry.

[30]  F. Caruso,et al.  Antitumor titanium compounds. , 2003, Mini reviews in medicinal chemistry.

[31]  Richard I. Cooper,et al.  CRYSTALS version 12: software for guided crystal structure analysis , 2003 .

[32]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[33]  A. Salifoglou,et al.  A new dinuclear Ti(IV)-peroxo-citrate complex from aqueous solutions. Synthetic, structural, and spectroscopic studies in relevance to aqueous titanium(IV)-peroxo-citrate speciation. , 2003, Inorganic chemistry.

[34]  E. Meléndez.  Titanium complexes in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[35]  Mitsuo Niinomi,et al.  Recent metallic materials for biomedical applications , 2002 .

[36]  D. Kerr,et al.  Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Niebch,et al.  Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane , 1995, Investigational New Drugs.

[38]  David J. Watkin,et al.  The control of difficult refinements , 1994 .

[39]  P. Koepf-Maier,et al.  Non-platinum group metal antitumor agents. History, current status, and perspectives , 1987 .

[40]  H. Flack,et al.  On enantiomorph‐polarity estimation , 1983 .

[41]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[42]  H. Tompa,et al.  The absorption correction in crystal structure analysis , 1965 .

[43]  A. Rajini,et al.  Synthesis, characterization, antimicrobial and cytotoxicity studies of a novel titanium dodecylamino phosphate , 2017 .

[44]  Mitsuo Niinomi,et al.  Mechanical biocompatibilities of titanium alloys for biomedical applications. , 2008, Journal of the mechanical behavior of biomedical materials.

[45]  H. Sperling,et al.  Phase II trial of titanocene dichloride in advanced renal-cell carcinoma , 1998, Cancer Chemotherapy and Pharmacology.

[46]  Edward Prince,et al.  Mathematical techniques in crystallography and materials science , 1982 .